Protalix BioTherapeutics, Inc. (PLX) stock is tumbling today: Why is it so?
Shares of the Protalix BioTherapeutics, Inc. (PLX) stock were tumbling today following the release of the updated data related to the clinical development of PRX-102 for the treatment of patients suffering from Fabry Disease. PLX stock price saw a downtrend of 14.77% to drop at $2.54 a share as of this writing. At the previous […]
